Automated Genetic Approaches in Yeast to Identify Novel Drug Targets for Alzheimer’s Disease and Parkinson’s Disease
Introduction Alzheimer’s disease and Parkinson’s disease are the two most common neurodegenerative disorders in the world, affecting at least 11 million people in developed countries. To date there are very few drugs on the market for these devastating disorders, and the drugs that are available provide only modest and temporary relief of some disease symptoms, while doing nothing to slow down disease progression. Technology description A novel automated approach has been developed to identify drug targets for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases, and to screen for small molecule inhibitors of those targets that can ultimately be used to treat the disorders. Business opportunity Total global revenues for treating Alzheimer ’s disease and Parkinson’s disease were $4.7 billion and $1.7 billion respectively in 2003. This technology allows an understanding of the molecular etiology of these diseases and identification of targets for drug development that would actually slow disease progression. Stage of development Identification of potential targets involved in both suppressing and enhancing disease progression has been performed. Further identification and validation across multiple neurodegenerative diseases will significantly enhance the value of the intellectual property portfolio. Intellectual property position US utility patent applications have been filed on this technology, and international coverage is available.
Type of Offer:
« More Diagnostic Patents